Management of Acute Pelvic Inflammatory disease
This is the second edition of this guideline, which was previously published in 2003 under the same title. Minor revisions were made to this document in March 2009.
Pelvic inflammatory disease (PID) is usually the result of infection ascending from the endocervix causing endometritis, salpingitis, parametritis, oophoritis, tubo-ovarian abscess and/or pelvic peritonitis. While sexually transmitted infections (STIs) such as Chlamydia trachomatis and Neisseria gonorrhoeae have been identified as causative agents, additional STIs including Mycoplasma genitalium, anaerobes and other organisms may also be implicated. PID is a common cause of morbidity and accounts for one in 60 general practitioner consultations by women under the age of 45 years. Delays of only a few days in receiving appropriate treatment markedly increase the risk of sequelae, which include infertility, ectopic pregnancy and chronic pelvic pain. Sequelae may also have significant healthcare costs. This guideline applies to women requiring treatment for confirmed or suspected acute PID being treated in an outpatient or inpatient setting by primary and secondary care practitioners. There are marked variations in the antimicrobial regimens used in the treatment of PID, reflecting uncertainty in the optimal treatment schedule. The guideline contains recommendations for treatment and graded evidence to support their use.
This guideline is available to download as a pdf :
A Russian language translation of this guideline is also available:
